Molecular characterization and clinical outcomes in EGFR-mutant de novo MET-overexpressed advanced non-small-cell lung cancer

BACKGROUND: Approximately 2%-8% of non-small-cell lung cancer (NSCLC) harbors concurrent epidermal growth factor receptor (EGFR) sensitizing mutation and mesenchymal–epithelial transition factor (MET) amplification prior to EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy. This study aimed to inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Mi, J., Huang, Z., Zhang, R., Zeng, L., Xu, Q., Yang, H., Lizaso, A., Tong, F., Dong, X., Yang, N., Zhang, Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717426/
https://www.ncbi.nlm.nih.gov/pubmed/34953403
http://dx.doi.org/10.1016/j.esmoop.2021.100347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717426/
https://www.ncbi.nlm.nih.gov/pubmed/34953403
http://dx.doi.org/10.1016/j.esmoop.2021.100347

Ejemplares similares